Vor Biopharma Inc. (NASDAQ:VOR – Get Free Report)’s share price crossed above its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $20.82 and traded as high as $21.74. Vor Biopharma shares last traded at $20.91, with a volume of 967,944 shares traded.
Wall Street Analysts Forecast Growth
A number of equities analysts have weighed in on the company. Weiss Ratings raised Vor Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, September 14th. William Blair started coverage on Vor Biopharma in a research note on Wednesday, October 21st. They issued an “outperform” rating for the company. Wedbush lifted their price target on Vor Biopharma from $18.00 to $27.00 and gave the stock a “neutral” rating in a report on Wednesday, August 12th. Wall Street Zen raised shares of Vor Biopharma from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Finally, Citigroup raised shares of Vor Biopharma to a “strong-buy” rating in a research report on Thursday, October 15th. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $38.00.
Check Out Our Latest Stock Report on Vor Biopharma
Vor Biopharma Price Performance
The firm has a 50-day simple moving average of $20.82 and a two-hundred day simple moving average of $17.31.
Vor Biopharma (NASDAQ:VOR – Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.11). Equities research analysts anticipate that Vor Biopharma Inc. will post -2.56 earnings per share for the current year.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in VOR. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Vor Biopharma during the 3rd quarter worth about $58,000. China Universal Asset Management Co. Ltd. lifted its stake in Vor Biopharma by 25.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,795 shares of the company’s stock worth $198,000 after purchasing an additional 2,171 shares during the last quarter. Engineers Gate Manager LP boosted its holdings in Vor Biopharma by 37.5% in the second quarter. Engineers Gate Manager LP now owns 36,951 shares of the company’s stock valued at $680,000 after purchasing an additional 10,071 shares in the last quarter. Braidwell LP boosted its holdings in Vor Biopharma by 22.8% in the second quarter. Braidwell LP now owns 573,104 shares of the company’s stock valued at $10,551,000 after purchasing an additional 106,330 shares in the last quarter. Finally, Wellington Management Group LLP acquired a new position in Vor Biopharma in the second quarter valued at approximately $499,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.
About Vor Biopharma
Vor Biopharma Inc is a clinical-stage biotechnology company focused on developing engineered hematopoietic stem cell therapies for the treatment of cancer, particularly blood cancers. The company combines gene-editing technologies with targeted immunotherapies to address limitations associated with conventional cancer treatments.
Vor’s platform is designed to create engineered hematopoietic stem cells that can protect healthy blood-forming cells from targeted therapies. Its lead program, VOR33, is an investigational CD33-edited hematopoietic stem cell therapy intended to support the use of CD33-targeted treatments in patients with acute myeloid leukemia.
Read More
- Five stocks we like better than Vor Biopharma
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for Vor Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vor Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
